More News! 18 Jun 2018 Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […] June 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2018 London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […] June 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 15 Jun 2018 This Israeli Biotech is Making Cultured Meat More Like the Real Thing Today, we’re in Ashdod, Israel, visiting Aleph Farms, a biotech that’s making cultured meat grown in a 3D environment that resembles the texture of natural meat. Mission: Founded in 2017, Aleph Farms uses cell samples taken from living cattle to create cultured meat. The cells are then grown in a 3D environment, which can help […] June 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Device Helps Protect Cereals by Diagnosing Herbicide Resistance in Weeds Mologic and Newcastle University have launched a diagnostic device that provides rapid information on herbicide resistance for a common weed, which could help cut major losses for the British agricultural industry. The partnership between academia and industry has developed a device that can diagnose herbicide resistance in the blackgrass weed, which could help farmers protect […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease Spanish researchers have developed a way to diagnose neurodegenerative diseases by analyzing eye movements. The Madrid-based research team and its spin-off company Aura Innovative Robotics have developed a diagnostic test for neurodegenerative disease that tracks a patient’s eye movements and analyzes the data using machine learning. The diagnostic test, called OSCANN Desk, is currently being […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2018 French Biotech Develops a New Generation of Safer CAR-T Cells Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of CAR-T cell therapies generated from both patient and donor cells. Cellectis, a French biotech focused on developing CAR-T therapies from donor cells, has published a study in the journal Scientific Reports describing technological advances that could improve the […] June 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 13 Jun 2018 CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were exhausted. However, the technology still has a long road ahead before becoming a widespread treatment option. Philip spoke to Christian Homsy, CEO of Celyad, at our Refresh Meetup in Brussels about the challenges CAR-T cell […] June 13, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2018 Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder Saniona, a biotech focused on ion channel research, plans to test its lead candidate in a Phase IIa study for the rare eating disorder hypothalamic obesity. Saniona, based in Copenhagen, plans to start a Phase IIa trial testing its product, Tesomet, a combination of tesofensine and metoprolol, in hypothalamic obesity. The study would complement the […] June 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 8 Jun 2018 The Textile Industry May Soon Turn to Insects to Help Produce Fabrics German researchers are exploring ways of using chitosan, which is derived from a component of insect skin called chitin, to replace toxic chemicals in the production of textiles. The researchers, who are based at the Fraunhofer Institute for Interfacial Engineering and Biotechnology in Stuttgart, plan to commercialize their technology and are already working with several […] June 8, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 8 Jun 2018 This Israeli Biotech Engineers Tobacco Plants to Make Collagen This week we’re in Ness Ziona, Israel, visiting CollPlant, a biotech that engineers tobacco plants to produce collagen for a variety of uses, including 3D printing and artificial tendons. Mission: CollPlant engineers tobacco plants to express five human genes, which enables the plants to produce recombinant human collagen. The material can be used in different […] June 8, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2018 Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s first biotechs, to develop microbiome-based treatments for inflammatory bowel disease. Microbiotica, based in Cambridge, UK has entered into a collaboration with Genentech that could be worth up to €452M ($534M), a formidable amount in the microbiome space, with an undisclosed […] June 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2018 German DNA Treatment Reduces Ulcerative Colitis Symptoms Sterna Biologicals has obtained positive Phase IIa data for an ulcerative colitis treatment that uses DNA to inhibit inflammatory proteins, which could add to the diverse approaches being developed to treat inflammatory bowel disease. Sterna Biologicals, based in Marburg, Germany, has clinical data showing its ulcerative colitis treatment reduced the severity of the disease compared […] June 6, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email